骨髓间充质干细胞对多发性骨髓瘤患者树突状细胞的影响

doi:10.3969/j.issn.1671-7171.2021.10.023

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1712 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate effects of multiple myeloma (MM) patients with bone marrow derived mesenchymal stem cell (MSC) on differentiation, maturation and cytokinese cretion of dendritic cell (DC) and its effect on DC helper T cell skilling myeloma cells. 【Methods】MSC cells from MM patients and healthy volunteers were mixed and cultured with DC, T cells and myeloma cell line U266 cells. DC immunophenotype was detected by flow cytometry, and cell apoptosis were measured by Annexin V-FITC/PI double labeling. 【Results】Culture supernatant TGF-β1 level of healthy persons' MSC cells was (60.52±2.83)pg/mL, which was significantly lower than that in MM patients (302.51±70.52) pg/mL; Tthe difference was statistical significance (P<0.05). Co-culture of MSC and immature/ mature DC cells showed that CD1a,CD11C,CD80,CD83,CD86, IL-12 secretion and HLA-DR expression were significantly suppressed(P<0.05). When T cells+ DC+ U266 were cultured together, the apoptosis rate in U266 cells was (72.24±8.63)%; While co-culturing T cell+DC+U266+ MSC from MM patients, the apoptosis rate in U266 cells was (45.56±9.22)%; When mixing T cell+DC,U266 cells with MSC from healthy persons, the apoptosis rate in U266 cells was (25.53±7.31)%. All differences were statistically significant (P<0.05). 【Conclusion】MSC from MM patients can significantly inhibit DC differentiation, maturation and cytokine secretion, and inhibit the killing effect of DC helper T cells.

Key words： Multiple Myeloma Myeloid Progenitor Cells/CY Dendritic Cells

Received: 13 May 2021

PACS:

R733.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Yan-yan

Cite this article:

MA Yan-yan. Effects of Bone Marrow-derived Mesenchymal Stem Cells on Dendritic Cells in Patients with Multiple Myeloma[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1522-1525.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.10.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I10/1522

[1] 段奎甲,王向鹏,杨智勇,等.GDNF基因修饰神经干细胞移植治疗大鼠帕金森病[J].南方医科大学学报,2016,36(1):32-38.
[2] 郭智,陈惠仁,刘晓东,等.异基因造血干细胞移植后发生巨细胞病毒感染的临床分析[J].国际病毒学杂志,2016,23(3):971-974.
[3] 赵霞,丁慧芳,徐敏,等.DC-CIK联合化疗治疗初发多发性骨髓瘤的疗效及对其Treg细胞功能的影响[J].中国实验血液学杂志,2016,24(1):122-126.
[4] 夏祖耀,杨惠娟,陈宝安.多发性骨髓瘤骨病治疗研究进展[J].中国实验血液学杂志,2016,24(1):275-278.
[5] 张雪伟,张燕丽,文泽馨,等.肿瘤来源的调节性树突状细胞的研究进展[J].国际免疫学杂志,2018,41(5):550-554.
[6] 中国医师协会血液科医师分会.中国多发性骨髓瘤诊治指南(2017年修订)[J].中华内科杂志,2017,56(11):112-114.
[7] DIMOPOULOS MA, ORIOL A, NAHI H, et al.Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma[J].N Engl J Med,2016, 375(14):1319-1331.
[8] MOREAU P,MASSZI T,GRZASKO N,et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.[J].N Engl J Med,2016, 374(17):1621.
[9] LONIAL S,WEISS B M,USMANI S Z,et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial[J].Lancet,2016,387(27):1551-1560.
[10] PICHIORRI F, SUH S S, ROCCI A, et al.Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.[J].Cancer Cell,2016, 18(4):367-381.
[11] SONNEVELD P,BROIJ A.Treatment of relapsed and refractory multiple myeloma[J].Haematologica,2016, 101(4):396-406.
[12] SONNEVELD P,AVET-LOISEAU H,LONIAL S,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group - ScienceDirect[J].Blood,2016,127(24):2955-2962.